S&P 500
5,985.96
+0.3%
+$15.59
DJI
42,578.31
+0.1%
+$58.67
NASDAQ
19,478.50
+0.4%
+$79.54
Bitcoin
105,202.00
-0.7%
-777.49
AAPL
$203.25
-0.0%
-$0.02
AMZN
$207.66
+0.9%
+$1.95
GOOG
$169.03
+0.8%
+$1.32
META
$684.25
+2.6%
+$17.40
MSFT
$464.75
+0.4%
+$1.78
NVDA
$141.14
-0.1%
-$0.08
TSLA
$334.14
-2.9%
-$10.13
Processa Pharmaceuticals (NASDAQ: PCSA)
$0.32
(9.7%)
$0.03
Price as of June 4, 2025, 1:41 p.m. ET
Processa Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Processa Pharmaceuticals Company Info
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.